These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Use of a purified non-protein bacterial component, piromen, in allergic conditions. ARONOFF S; GHAEMI A J Med Soc N J; 1953 Dec; 50(12):564-7. PubMed ID: 13109447 [No Abstract] [Full Text] [Related]
45. Pharmacological activities of natural triterpenoids and their therapeutic implications. Dzubak P; Hajduch M; Vydra D; Hustova A; Kvasnica M; Biedermann D; Markova L; Urban M; Sarek J Nat Prod Rep; 2006 Jun; 23(3):394-411. PubMed ID: 16741586 [No Abstract] [Full Text] [Related]
46. Natural products and production systems: opening comments. Pfeifer B Mol Pharm; 2008; 5(2):165-6. PubMed ID: 18302320 [No Abstract] [Full Text] [Related]
47. [Natural products in clinical trials: antiparasitic, antiviral and neurological drugs]. Zheng D; Han L; Huang XS; Yu SS; Liang XT Yao Xue Xue Bao; 2007 Jun; 42(6):576-82. PubMed ID: 17702391 [TBL] [Abstract][Full Text] [Related]
48. [Psoriasis. How much promise for immunobiologic therapy?]. Musch A Med Monatsschr Pharm; 2005 Aug; 28(8):262-6. PubMed ID: 16128537 [No Abstract] [Full Text] [Related]
50. Natural products as drug leads: an old process or the new hope for drug discovery? Kingston DG; Newman DJ IDrugs; 2005 Dec; 8(12):990-2. PubMed ID: 16320131 [TBL] [Abstract][Full Text] [Related]
51. Clinical pharmacology in the era of biotherapeutics. Lalonde RL; Honig P Clin Pharmacol Ther; 2008 Nov; 84(5):533-6. PubMed ID: 18941451 [No Abstract] [Full Text] [Related]
52. Measuring the impact of managed care plans on the use of biologics. Furst DE Arthritis Rheum; 2005 Jun; 53(3):318-9. PubMed ID: 15934125 [No Abstract] [Full Text] [Related]
53. Introduction. Gottlieb AB Dermatol Ther; 2009; 22(1):1. PubMed ID: 19222512 [No Abstract] [Full Text] [Related]
55. Prosthetics and biologics: the wave of the future. Traynelis VC Clin Neurosurg; 2003; 50():207-19. PubMed ID: 14677439 [No Abstract] [Full Text] [Related]
56. [Biologicals are the first choice for RA treatment -- contra]. Krüger K Dtsch Med Wochenschr; 2005 Aug; 130(33):1901. PubMed ID: 16118737 [No Abstract] [Full Text] [Related]
57. [New therapy option for problem patients. What is the value of "biologics" in psoriasis?]. Boehncke WH MMW Fortschr Med; 2004 Nov; 146(46):45. PubMed ID: 15600044 [No Abstract] [Full Text] [Related]
58. New frontiers of therapy in hemato-oncology. Prabhash K; Bapsy PP J Assoc Physicians India; 2003 Nov; 51():1123-4; author reply 1124. PubMed ID: 15260408 [No Abstract] [Full Text] [Related]